Body Substance
Novo Nordisk Acquires Rights to Omeros’ MASP-3 Inhibitor Zaltenibart
Novo Nordisk; Omeros; Zaltenibart; MASP-3 Inhibitor; Rare Blood and Kidney Disorders
NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degrader
Pooled Sample, Obicetrapib, BROADWAY, NewAmsterdam, LDL-C, Cardiovascular Diseases